i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Development Pipeline
Home R & D Pipeline

Pipeline

COVID 19 & ARDS
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
Critical COVID-19

US EUA granted

SARS-CoV-2-induced ARDS

Approved by European Commission*

Broader ARDS

Phase 2 "Just Breathe" ASPR/BARDA clinical platform study

INFLAMMATION & IMMUNOLOGY (I&I)
Program
Preclinical
Phase 1
Phase 2
Phase 3
Market
Status & Milestones
Pyoderma Gangraenosum

Enrollment ongoing; 
Interim analysis for adaption and futility anticipated by the end of May 2025

Chronic spontaneous urticaria (CSU)

Data anticipated in Summer 2025

Hidradenitis suppurativa (HS)

Data anticipated in Summer 2025

Other immuno-dermatology

Additional indications in immuno-dermatology

Vilobelimab Life-cycle approach

For optimized use in chronic inflammatory indications

various

Additional chronic indications in I&I including neurology, nephrology, hematology and others

*Commercial partnering and distribution options in the EU being considered.



 

See also in R&D: